In summary, these data suggest that TGF-β1, Dkk1, and IL-17A IHC in PsA and RA patients could anticipate the need for biological therapies, but these findings need to be approached carefully until they are confirmed by larger studies in the future. Here, IL17A is linked to rheumatoid arthritis.